Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency makes clear that triglyceride levels are no longer an acceptable surrogate for reducing cardiovascular risk.

You may also be interested in...



Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template

Circumstances of FDA's approval of Sarepta's Exondys 51 approval may give BioMarin reason to appeal the complete response for its Duchenne muscular dystrophy treatment drisapersen – but its high-quality data could preclude success.

Special Protocol Assessment Draft Guidance Adds Biosimilars, Not Much Clarity

SPA can be terminated by 'substantial scientific issue,' FDA tells industry, but notes that it only happens less than one percent of the time.

Advicor, Simcor Withdrawals Show There's A Lot Riding On CV Outcomes Studies

Surrogate markers for cardiovascular products may be going the way of AbbVie's cholesterol franchise.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel